Genetic Technologies Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Genetic Technologies Limited (GENE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Genetic Technologies Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 8M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Peer revenue share: Genetic Technologies Limited accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GENE Sales vs. its Competitors, Q4 2024
Genetic Technologies Limited generated 100.00 % of the combined sales of its peer group.
Genetic Technologies Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Genetic Technologies Limited | - | - | - | - |
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GENE Stock Performance relative to its Competitors
GENE Stock Performance relative to High-Confidence Competitors
Genetic Technologies Limited's Comment on Competition and Industry Peers
Genetic Technologies Limited's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ancestry.com | Named by the company | 85% |
| Gene by Gene | Named by the company | 85% |
| MyHeritage | Named by the company | 85% |
| 23andMe | Named by the company | 85% |
| Counsyl Inc. | Named by the company | 85% |
| Invitae Corporation | Named by the company | 85% |
| ThermoFisher | Named by the company | 85% |
| AncestryDNA | Named by the company | 85% |
| Genomics PLC | Named by the company | 85% |
| Myriad Genetic Laboratories Inc. | Named by the company | 85% |
| Ambry Genetics Corporation | Named by the company | 85% |
| deCODE | Named by the company | 85% |
| Life Technologies | Named by the company | 85% |
| Color Genomics | Named by the company | 85% |
| Intergenetics | Named by the company | 85% |
| Navigenics | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Genetic Technologies Limited's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.